sgp(schering plough) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sgp(schering plough)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jbe who wrote (16)	12/11/1997 1:06:00 PM
From: JBruin	Read Replies (2) of 117

jbe, <What about prospects, etc.? Any ideas?> My opinion is that there are two major events that would have a significant impact on earnings estimates. The first is the Japan approval for Claritin (I'm not sure if you guys already covered this on the thread, I didn't read through all of them). Claritin has approx. 60-70% of the US antihistamine market and given the size of the Japanese market the impact on revenues/earnings would be sizeable. The second is the potential of the Sepracor DCL formulation of Claritin. If the tests of this "new and improved" Claritin go well, then SGP could effectively extend its patent expiration from 2004 to 2014. The possible launch of the DCL formulation would probably be 2001-2 but this assumes the tests go okay. Anybody other ideas? Comments?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next